30349257|t|Postseizure aphasia in Wernicke's encephalopathy: a case report and review of literature.
30349257|a|This case discusses the course of a woman with a history of epilepsy, alcohol use disorder, herpes simplex virus (HSV) encephalitis, and Wernicke encephalopathy (WE) who presented with altered mental status following approximately 48 hours of vomiting. After experiencing a tonic-clonic seizure in the emergency department, she developed a fluent aphasia. Aphasias are ordinarily attributed to structural changes in the brain parenchyma, often from stroke, neoplasm, or infection. When the magnetic resonance imaging of brain failed to show changes that could explain her fluent aphasia, the neurology team consulted psychiatry to workup psychogenic aphasia. During an admission 9 months earlier, she had been diagnosed with HSV encephalitis and possible WE. There was a high degree of suspicion for recurrent HSV infection, intermittent focal seizure activity, postictal psychosis, pseudobulbar affect, or a vascular cause of her fluent aphasia. After 3 days of treatment with levetiracetam, high-dose intravenous thiamine, and aripiprazole, the patient's fluent aphasia reversed. The authors conclude that the patient's reversible fluent aphasia was not psychiatric in etiology but likely caused by her seizures, the result of subtherapeutic phenytoin levels; her electroencephalogram showed focal seizure activity in the temporal lobes, possibly affecting her language centers. Language-related neurological conditions, or aphasias, can mimic psychiatric conditions such as conversion disorder or psychosis. In patients with substance use disorders, the line between psychiatric and neurological conditions becomes even more difficult to distinguish. The paper also discusses how unique aspects of her medications - levetiracetam conferring neuron membrane fluidity; aripiprazole, a drug shown to halt brain atrophy in mouse models; and parenteral thiamine to address her deficiency and WE - have aided in the reversal of the fluent aphasia. Levetiracetam should be considered in WE and the rare occurrence of aphasia after seizures.
30349257	0	19	Postseizure aphasia	Disease	MESH:D001037
30349257	23	48	Wernicke's encephalopathy	Disease	MESH:D014899
30349257	126	131	woman	Species	9606
30349257	150	158	epilepsy	Disease	MESH:D004827
30349257	160	180	alcohol use disorder	Disease	MESH:D000437
30349257	182	221	herpes simplex virus (HSV) encephalitis	Disease	MESH:D020803
30349257	227	250	Wernicke encephalopathy	Disease	MESH:D014899
30349257	252	254	WE	Disease	MESH:D014899
30349257	333	341	vomiting	Disease	MESH:D014839
30349257	364	384	tonic-clonic seizure	Disease	MESH:D012640
30349257	430	444	fluent aphasia	Disease	MESH:D001041
30349257	446	454	Aphasias	Disease	MESH:D001037
30349257	539	545	stroke	Disease	MESH:D020521
30349257	547	555	neoplasm	Disease	MESH:D009369
30349257	560	569	infection	Disease	MESH:D007239
30349257	662	676	fluent aphasia	Disease	MESH:D001041
30349257	728	747	psychogenic aphasia	Disease	MESH:D001037
30349257	815	831	HSV encephalitis	Disease	MESH:D020803
30349257	845	847	WE	Disease	MESH:D014899
30349257	900	913	HSV infection	Disease	MESH:D006561
30349257	934	941	seizure	Disease	MESH:D012640
30349257	952	971	postictal psychosis	Disease	MESH:D011618
30349257	973	992	pseudobulbar affect	Disease	MESH:D020828
30349257	1021	1035	fluent aphasia	Disease	MESH:D001041
30349257	1068	1081	levetiracetam	Chemical	MESH:D000077287
30349257	1105	1113	thiamine	Chemical	MESH:D013831
30349257	1119	1131	aripiprazole	Chemical	MESH:D000068180
30349257	1137	1144	patient	Species	9606
30349257	1147	1161	fluent aphasia	Disease	MESH:D001041
30349257	1202	1209	patient	Species	9606
30349257	1223	1237	fluent aphasia	Disease	MESH:D001041
30349257	1246	1257	psychiatric	Disease	MESH:D001523
30349257	1295	1303	seizures	Disease	MESH:D012640
30349257	1334	1343	phenytoin	Chemical	MESH:D010672
30349257	1390	1397	seizure	Disease	MESH:D012640
30349257	1471	1511	Language-related neurological conditions	Disease	MESH:D007806
30349257	1516	1524	aphasias	Disease	MESH:D001037
30349257	1536	1558	psychiatric conditions	Disease	MESH:D001523
30349257	1567	1586	conversion disorder	Disease	MESH:D003291
30349257	1590	1599	psychosis	Disease	MESH:D011618
30349257	1604	1612	patients	Species	9606
30349257	1618	1641	substance use disorders	Disease	MESH:D019966
30349257	1660	1671	psychiatric	Disease	MESH:D001523
30349257	1676	1699	neurological conditions	Disease	MESH:D019636
30349257	1809	1822	levetiracetam	Chemical	MESH:D000077287
30349257	1860	1872	aripiprazole	Chemical	MESH:D000068180
30349257	1895	1908	brain atrophy	Disease	MESH:C566985
30349257	1912	1917	mouse	Species	10090
30349257	1941	1949	thiamine	Chemical	MESH:D013831
30349257	1980	1982	WE	Disease	MESH:D014899
30349257	2019	2033	fluent aphasia	Disease	MESH:D001041
30349257	2035	2048	Levetiracetam	Chemical	MESH:D000077287
30349257	2073	2075	WE	Disease	MESH:D014899
30349257	2103	2110	aphasia	Disease	MESH:D001037
30349257	2117	2125	seizures	Disease	MESH:D012640
30349257	Negative_Correlation	MESH:D000077287	MESH:D014899
30349257	Negative_Correlation	MESH:D013831	MESH:D001041
30349257	Negative_Correlation	MESH:D013831	MESH:D014899
30349257	Negative_Correlation	MESH:D000068180	MESH:C566985
30349257	Negative_Correlation	MESH:D000077287	MESH:D001037
30349257	Association	MESH:D010672	MESH:D012640
30349257	Negative_Correlation	MESH:D000068180	MESH:D014899
30349257	Negative_Correlation	MESH:D000077287	MESH:D001041
30349257	Association	MESH:D010672	MESH:D001041
30349257	Negative_Correlation	MESH:D000077287	MESH:D012640
30349257	Negative_Correlation	MESH:D000068180	MESH:D001041

